Recombinantly modified plasmin
View Patent ↗Polynucleotides and polypeptides relating to a recombinantly modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, combined such that no foreign sequences are present, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.
1. A method for making a recombinant plasmin polypeptide, the method comprising:
(a) providing a polypeptide having a single N-terminal kringle domain wherein the last four amino acid residues within the kringle domain are identical to residues at positions 91-94 of SEQ ID NO: 2; and a C-terminal domain activation site and serine protease domain;
wherein the polypeptide binds to immobilized lysine; and
wherein the polypeptide is at least 95% identical to the sequence shown in SEQ ID NO: 2;
(b) contacting the polypeptide provided in step (a) with a protease under conditions sufficient to cleave one or more peptide bonds thereby forming an active recombinant plasmin polypeptide.
2. The method of claim 1 , wherein the polypeptide has an amino acid sequence shown in SEQ ID NO: 2.
3. The method of claim 1 , wherein providing comprises expressing a DNA sequence shown in SEQ ID NO: 1, or a degenerate variant thereof, in E. coli.
4. The method of claim 1 , wherein the polypeptide is at least 98% identical to the sequence shown in SEQ ID NO: 2.
5. The method of claim 1 , wherein amino acid residues 2-9 of the polypeptide are identical to residues at positions 2-9 of SEQ ID: NO: 2.
6. The method of claim 1 , wherein the polypeptide has the amino acid sequence shown in SEQ ID NO: 2 with no more than 15 amino acid substitutions.
7. The method of claim 1 , wherein the polypeptide has the amino acid sequence shown in SEQ ID NO: 2 with no more than 10 amino acid substitutions.
8. The method of claim 1 wherein the polypeptide has the amino acid sequence shown in SEQ ID NO: 2 with no more than 8 amino acid substitutions.
9. The method of claim 1 , wherein the polypeptide has the amino acid sequence shown in SEQ ID NO: 2 with no more than 5 amino acid substitutions.
10. The method of claim 1 , wherein the polypeptide has the amino acid sequence shown in SEQ ID NO: 2 with no more than 3 amino acid substitutions.
11. The method of claim 1 , wherein the polypeptide exhibits a lower binding affinity for fibrinogen than the binding affinity for fibrinogen of mini-plasmin.
12. The method of claim 1 , wherein the polypeptide exhibits higher binding affinity for partially cleaved fibrin than the binding affinity for partially cleaved fibrin of mini-plasmin.
13. The method of claim 1 , wherein the polypeptide exhibits a fibrinolytic activity that is inhibited by α2-antiplasmin at a rate of inhibition that is at least about 5-fold faster than the rate of inhibition of the fibrinolytic activity of mini-plasmin by α2-antiplasmin.
14. The method of claim 1 , wherein the rate of inhibition is at least 10-fold to 40-fold faster than the rate of inhibition of miniplasmin.
15. The method of claim 1 , wherein the immobilized lysine is lysine bound to a solid support matrix selected from the group consisting of lysine-agarose, lysine-hydrogel, and lysine-cross-linked agarose.
16. The method of claim 14 , wherein the immobilized lysine is lysine-cross-linked agarose.
17. The method of claim 1 , wherein the polypeptide has reduced immunogenicity as compared to a reference polypeptide, wherein the reference polypeptide has a primary amino acid sequence identical to the primary amino acid sequence of the polypeptide; with the proviso that the last four amino acid residues of the single N-terminal kringle domain of the reference polypeptide are not identical to residues at positions 91-94 of SEQ ID NO: 2.
18. The method of claim 1 , wherein the protease is streptokinase, urokinase, or tissue plasminogen activator (tPA).
19. The method of claim 1 , wherein the protease is streptokinase.